Rare cancer survival predictor developed
NCT ID NCT07179341
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at 156 patients with thymic carcinoma, a rare and aggressive chest cancer. Researchers created a tool called a nomogram that uses patient data to predict how long someone might live after diagnosis. The tool was tested on three groups of patients and showed promise in estimating survival, but it needs more research before it can be used in clinics.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this tool could help doctors better predict survival for thymic carcinoma patients, guiding treatment decisions.
- What could go wrong
- This is a small, single-center study based on past data. The tool needs testing in larger, diverse groups before it can be widely used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New combo therapy shows promise for rare chest cancer
- New trial aims to stop thymic cancer return with Chemo-Radiation combo